What is Creyon Bio?
Creyon Bio is a pre-clinical stage company dedicated to transforming drug development. By leveraging a data-first methodology, the company generates powerful datasets and develops advanced machine learning models. These tools are designed to uncover the engineering principles essential for creating precision oligonucleotide-based medicines, aiming to serve patient populations of all sizes. The company's focus on uncovering fundamental principles suggests a deep scientific and technological underpinning to its drug discovery efforts.
How much funding has Creyon Bio raised?
Creyon Bio has raised a total of $40M across 1 funding round:
Series A
$40M
Series A (2022): $40M with participation from Lux Capital, DCVC Management, BioBrit, Alexandria, and Casdin Capital
Key Investors in Creyon Bio
Lux Capital
Lux Capital is a New York-based venture capital firm specializing in early-stage and growth-stage companies at the intersection of science and technology, including biotechnology.
DCVC Management
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling challenging problems, with a focus on leveraging artificial intelligence across sectors including biotechnology.
Alexandria
Alexandria Real Estate Equities, Inc. is a real estate investment trust (REIT) that owns, operates, and develops properties for the life sciences industry, supporting pharmaceutical and biotechnology entities.
What's next for Creyon Bio?
With the recent major strategic investment and substantial total funding, Creyon Bio is poised for accelerated growth and development. The substantial capital infusion, particularly the enterprise-level backing, indicates strong investor confidence in the company's unique approach to precision medicine. This financing will likely fuel further research and development, enhance its machine learning capabilities, and potentially expand its pipeline of oligonucleotide-based therapeutics. The company's trajectory suggests a move towards clinical validation and broader market penetration in the competitive biotechnology landscape.
See full Creyon Bio company page
